Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

APGE

Apogee Therapeutics Inc.

Jul 26 • 04:00PM ET

49.95

Dollar change +1.29
Percentage change 2.65	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI XBI IWO VXF IBB SCHA VTWO LABU VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	0.90%	Shs Outstand	37.17M	Perf Week	5.16%
Market Cap	1.86B	Forward P/E	-	EPS next Y	-3.24	Insider Trans	-5.90%	Shs Float	36.85M	Perf Month	30.59%
Income	-	PEG	-	EPS next Q	-0.61	Inst Own	118.49%	Short Float	23.37%	Perf Quarter	8.92%
Sales	-	P/S	-	EPS this Y	22.77%	Inst Trans	-	Short Ratio	18.57	Perf Half Y	38.40%
Book/sh	13.71	P/B	3.64	EPS next Y	-25.00%	ROA	-	Short Interest	8.61M	Perf Year	137.52%
Cash/sh	21.95	P/C	2.28	EPS next 5Y	-	ROE	-	52W Range	14.19 - 72.29	Perf YTD	78.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-30.90%	Beta	2.56
Dividend TTM	-	Quick Ratio	38.08	Sales past 5Y	0.00%	Gross Margin	-	52W Low	252.01%	ATR (14)	2.83
Dividend Ex-Date	-	Current Ratio	38.08	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	62.03	Volatility	6.49% 6.18%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	84.83
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-158.66%	Payout	-	Rel Volume	0.74	Prev Close	48.66
Sales Surprise	-	EPS Surprise	-7.38%	Sales Q/Q	-	Earnings	May 13 BMO	Avg Volume	463.85K	Price	49.95
SMA20	12.46%	SMA50	12.11%	SMA200	29.94%	Trades		Volume	341,121	Change	2.65%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-06-24 01:00AM	Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
May-28-24 07:30AM	Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD (GlobeNewswire)
May-23-24 07:30AM	Apogee Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
04:01PM	Loading…
May-15-24 04:01PM	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
May-13-24 01:53PM	APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:42AM	Apogee Therapeutics' Q1 Net Loss Widens (MT Newswires)
07:00AM	Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-10-24 10:13AM	BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target (MT Newswires)
May-08-24 01:28PM	Earnings Superstars: 3 Stocks Primed to Outperform This Quarter (InvestorPlace)
May-06-24 08:00AM	Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference (GlobeNewswire)
Apr-03-24 07:49AM	Paragons hub-and-spoke biotech model yields another reverse merger (BioPharma Dive)
Mar-28-24 11:01AM	Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why (Zacks)
Mar-25-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire) -5.01%
07:00AM	Loading…
07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire)
Mar-12-24 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million (GlobeNewswire)
Mar-07-24 06:49PM	Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering (GlobeNewswire)
Mar-05-24 10:53PM	APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +42.07% +12.46%
04:23PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
04:16PM	Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water (Investor's Business Daily)
07:35AM	IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome (Investor's Business Daily)
07:35AM	IPO Stock Apogee Rockets On Solid Phase 1 Outcome (Investor's Business Daily)
06:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:00AM	Apogee data hint at potential for long-lasting eczema drug (BioPharma Dive)
06:00AM	Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days (GlobeNewswire)
Mar-04-24 04:01PM	Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 (GlobeNewswire) +12.08%
Jan-02-24 07:30AM	Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-23 04:44AM	Apogee Therapeutics Inc Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
Nov-13-23 07:30AM	Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results (GlobeNewswire) +7.32%
08:00AM	Loading…
Oct-30-23 08:00AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire) +5.77%
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace) -8.07%
Sep-27-23 08:42AM	Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire)
Sep-14-23 07:30AM	Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day (GlobeNewswire)
Aug-29-23 08:00AM	Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics (PR Newswire)
Aug-28-23 07:30AM	Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-21-23 07:30AM	Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board (GlobeNewswire)
Aug-10-23 02:29PM	FMR LLC Acquires New Stake in Apogee Therapeutics Inc (GuruFocus.com)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-23 07:30AM	Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-02-23 07:30AM	Apogee Therapeutics to Participate in Upcoming August Investor Conferences (GlobeNewswire)
Jul-18-23 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jul 05 '24	Sale	37.26	15,000	558,900	1,474,487	Jul 05 08:01 PM
Dambkowski Carl	Chief Medical Officer	Jul 03 '24	Sale	37.60	5,995	225,418	294,793	Jul 05 08:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APGE

Apogee Therapeutics Inc.

Upgrade your FINVIZ experience